Quest diagnostics introduces specimen self-collection for common genital tract infection testing at nationwide network of patient service centers

First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and mycoplasma genitalium self-collection option  available at no extra charge at any of quest's 2,000 patient service centers with a physician's order or through quest's consumer-initiated test platform at questhealth.com secaucus, n.j. , oct. 15, 2024 /prnewswire/ -- quest diagnostics (nyse: dgx), a leader in diagnostic information services, today announced the availability of a new service aimed at increasing convenience and speed of testing and treatment of several common genital tract infections (gtis).
DGX Ratings Summary
DGX Quant Ranking